Biodesix Ranked Top Proteomics Solutions Company by Life Sciences Review Magazine

Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that the Company was named the leading Proteomics Solutions Company in the U.S. by Life Sciences Review Magazine, featured in the December 2022 issue, “Top 10 Proteomics Solutions Companies of 2022.” Biodesix is a market leader with over 15 years of experience in the field of clinical proteomics. The Company’s expertise focuses on profiling the patient’s immune response to their cancer with blood-based proteomic solutions, in addition to genomic insights. Biodesix’s core technologies and extensive machine learning and transparent AI expertise allow for identifying clinically relevant proteomic differences in patient populations to help guide treatment strategy. To date, Biodesix has performed over 125,000 proteomic tests for research and clinical use.

“We understand the importance of the circulating human proteome as a vital component of the disease,” says Kieran O’Kane, Chief Commercial Officer at Biodesix. “High-plex assays combine different proteins into a single diagnostic test to ensure better outcomes. We are honored to receive this recognition for our dedication to proteomic insights for patients and would like to congratulate the nine other esteemed proteomic solutions companies and teams recognized.”

Biodesix currently offers three clinical proteomic tests, using technologies such as Liquid Chromatography Mass Spectrometry (LC-MS), MALDI-ToF Mass Spectrometry, and Enzyme-Linked Immunosorbent Assay (ELISA). Nodify Lung testing consists of two blood-based proteomic tests, the Nodify CDT and Nodify XL2 tests, to help healthcare providers quickly decipher the risk of malignancy of a lung nodule. The VeriStrat proteomic test identifies a chronic inflammatory disease state associated with aggressive non-small cell lung cancer (NSCLC) in an average of 36-hour turnaround time without the need for tissue biopsy. The VeriStrat proteomic test is part of the IQLung treatment guidance testing strategy, which also includes the GeneStrat targeted genomic test and the GeneStrat NGS genomic test. IQLung testing provides a broader view of each patient’s disease state, with results delivered in average of 72 hours, empowering care teams with test results that inform treatment decisions for any stage of NSCLC.